Trial for Dogs with Mast Cell Tumors
Characterization of canine mast cell tumors and generation of primary cell lines
Purpose and Brief Study Description:
Mast cell tumors are the most common skin tumor in dogs, comprising between 16 and 21% of all canine malignant skin cancers. The currently accepted approach to therapy for high grade mast cell tumors is surgery followed by chemotherapy, or other adjuvant therapy.
This study is specifically focused on the generation and characterization of a panel of cell lines established from canine mast cell tumor tissues. Your participation in this study is only to donate your dog’s tumor tissue to a panel of other MCTs for further research. This panel of canine mast cell tumor cell lines will then be utilized by researchers for future investigations into mast cell-mediated disorders, specifically for the development of enhanced diagnostic, monitoring and treatment approaches for canine mast cell tumors. These canine mast cell tumor-derived cell lines will also be crucial to translational research by helping to further elucidate human mast cell neoplasia, and other human and canine diseases characterized by mast cell-mediated immune dysregulation.
- Client-owned dogs with cytologically and/or histologically confirmed diagnosis of mast cell tumor. Diagnosis and comprehensive staging will be required for each dog prior to study enrollment.
- Dogs of any breed, age, gender or weight, with satisfactory health are eligible.
- Non-steroidal anti-inflammatory therapy (NSAIDs) will be allowable with a minimum washout period of 72 hours prior to baseline evaluation and surgery.
- Dogs that have previously received radiation therapy and/or prior chemotherapy, including corticosteroids (including prednisone), would not be eligible for enrollment.
What does enrollment into this trial involve?
This study involves only the staging of the mast cell tumor disease and the use of the resected tumor tissue in in vitro research. Owners of dogs diagnosed with a suspected mast cell tumor that have already elected to have the tumor surgically removed, will be agreeing to donate their dog’s tumor tissue to this study.
The study will cover the cost of all screening/staging procedures, to include: complete blood work, urinalysis, cytology, histopathology, mast cell tumor panel, abdominal ultrasound (with image-guided aspirates of the spleen, liver, and lymph nodes), bone marrow aspirate, any sedation or anesthesia required to facilitate staging tests, and anti-histamines to mitigate any side effects due to MCT disease.
The owner is responsible for the cost of the initial Oncology consultation fee. The surgery to remove a mast cell tumor is NOT part of this study; therefore, the owners are responsible for all fees and risks associated with the surgical removal of a mast cell tumor.
For more information, please contact Misty Bear, Clinical Trials Coordinator: Phone: (785)532-3046, email: ClinicalTrials@vet.k-state.edu